The 24th International AIDS Conference
AIDS 2022 will take place from 29 July to 2 August 2022, with pre-conference meetings beginning on 27 July 2022.
The 24th International AIDS Conference (AIDS 2022) is the world’s largest conference on HIV and AIDS will be hosted in person in Montreal, Canada, as well as virtually. AIDS 2022 will call on the world to come together to re-engage and follow the science. It will define future research agendas, shift latest evidence to action, and chart a new consensus on overcoming the HIV epidemic as a threat to public health and individual well-being.
Listed below are AIDS 2022 sessions, symposia, and satellites affiliated with the HIV/AIDS Clinical Trials Networks. Session presenters marked with an asterisk (*) are affiliated with the HIV/AIDS Clinical Trials Networks.
All sessions are listed in Eastern Daylight Time (EDT), UTC-4.
More sessions will be added to this page as information becomes available. Please check back closer to the conference dates for a complete listing of HIV/AIDS Clinical Trials Network sessions
Preconference Events
Interfaith Preconference: Taking action to overcome HIV Stigma and Discrimination
Preconference Event, Montreal's La Plaza Centre-Ville-EVO
Workshop, Sofitel Montreal Golden Mile
| Associated Protocols | Abstract Title | Presenting Author | Format |
| PROMISE P1084s | Changes in bone turnover markers after delivery in breastfeeding mothers with and without ARVs | Kristin Baltrusaitis | Oral session |
Friday, July 29
Oral Abstract Session, OALBX01
| 11:45 2 min | Introduction Jean-Pierre Routy, Canada Adeeba Kamarulzaman, Malaysia |
| 11:47 8 min | Transcriptional programs of HIV silencing and cell survival in HIV-infected memory CD4 T cells under antiretroviral therapy Eli Boritz, Vaccine Research Center, NIAID, NIH USA, United States |
| 11:55 8 min | Doxycycline post-exposure prophylaxis for STI prevention among MSM and transgender women on HIV PrEP or living with HIV: high efficacy to reduce incident STI's in a randomized trial Annie Luetkemeyer, Zuckerberg San Francisco General Hospital, UCSF, United States |
| 12:03 8 min | Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir Disoproxil Fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE) Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS Research Centre, Thailand |
| 12:11 8 min | Trends in PrEP inequity by race and census region, United States, 2012-2021 Patrick Sullivan, Emory University, United States |
| 12:19 8 min | Long acting cabotegravir: updated efficacy and safety results from HPTN 084 *Sinead Delany-Moretlwe, University of Witwatersrand, South Africa |
| 12:27 13 min | Q&A Adeeba Kamarulzaman, Malaysia Jean-Pierre Routy, Canada Anchalee Avihingsanon, HIV-NAT, THai Red Cross AIDS Research Centre, Thailand *Sinead Delany-Moretlwe, University of the Witwatersrand, South Africa Eli Boritz, Vaccine Research Center, NIAID, NIH USA, United States Annie Luetkemeyer, Zuckerberg San Francsico General Hospital, UCSF, United States Patrick Sullivan, Emory University, United States |
| 12:40 5 min | IAS President's Award Adeeba Kamarulzaman, Malaysia Soumya Swaminathan |
Satellite Session, SA023
| 14:45 10 min | Experimental Medicine Vaccine Trials Robin Shattock, Imperial College, United Kingdom |
| 14:55 10 min | Status of HIV Vaccine Research Kundai Chinyenze, International AIDS Vaccine Initiative (IAVI), Kenya |
| 15:05 10 min | Experimental Medicine Vaccine Trials: community considerations, questions and perspectives Ntando Yola, Desmond Tutu HIV Foundation (DTHF), South Africa |
| 15:15 45 min | Panel Discussion Cathy Slack, HIV/AIDS Vaccine Ethics Group (HAVEG), South Africa Pervin Anklesaria, Bill & Melinda Gates Foundation (BMGF), United States Eunice Nduati, KEMRI Wellcome Trust Research Programme, Kenya Mary Marovich, National Institutes of Health (NIH), United States Maureen Luba, Global Advocacy for HIV Prevention (AVAC), Malawi *Nyaradzo Mavis Mgodi, University of Zimbabwe, Zimbabwe |
Satellite Session, SA024
| 14:45 10 min | Official launch of JIAS Supplement and overview of the framework to enhance and accelerate the study of new HIV drugs in pregnancy Annette Sohn, amfAR, the Foundation for AIDS Research, Thailand Martina Penazzato, WHO HQ, Switzerland *Elaine Abrams, IMPAACT Network & ICAP at Columbia University, United States |
| 14:55 25 min | Panel 1: Keeping momentum and generating tangible progress in accelerating research in pregnancy *Sinead Delany-Moretlwe, University of the Witwatersrand, South Africa Nahida Chakhtoura, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), United States Annemiek De Ruiter, ViiV Healthcare, United Kingdom Saye Khoo, University of Liverpool, United Kingdom Carmen Perez Casas, Unitaid, SwitzerlandLeyla SAHIN, U.S. Food and Drug Administration (FDA), United States |
| 15:20 25 min | Effective and meaningful support of participants in research Imelda Chipo Mahaka, Pangaea Zimbabwe AIDS Trust, Zimbabwe Mercy Shibemba, Penta Foundation, United Kingdom |
| 15:45 25 min | Panel 2: Amplifying impact by joining forces across disease areas to study new drugs during pregnancy Amita Gupta, Johns Hopkins Bloomberg School of Public Health, United States Carmen Perez Casas, Unitaid, Switzerland Myriam El-Gaaloul, Medicines for Malaria Venture, Switzerland Manal El-Sayed, Ain Shams University, Egypt Melanie Taylor, Centers for Disease Control and Prevention, United States |
| 16:10 5 min | Bringing it all together: charting the path towards more equitable access to novel therapeutics Meg Doherty, World Health Organization, Switzerland *Sharon Nachman, IMPAACT Network & Stony Brook University Hospital, United States |
Satellite Session, SA041
| 18:15 2 min | Introduction and welcome Nelli Barrière, International AIDS Society, Switzerland |
| 18:17 10 min | Role of the pharmaceutical industry in HIV prevention and vaccine research - A researcher's perspective *Linda-Gail Bekker, Desmond Tutu HIV Centre, South Africa |
| 18:27 10 min | Importance of community engagement with the pharmaceutical industry for HIV prevention research - A community perspective |
| 18:37 10 min | What does a successful public-private partnership for HIV vaccine R&D look like? *Dan Barouch, Center for Virology and Vaccine Research, BIDMC, United Statess |
| 18:47 15 min | IAS Global HIV Vaccine Enterprise Industry Partnership launch Birgit Poniatowski, International AIDS Society (IAS), Switzerland |
| 19:02 40 min | Panel discussion *Shan Lu, Worcester HIV Vaccine, United States |
| 19:42 3 min | Closing |
Saturday, July 30
Satellite Session, SA046
| 8:00 5 min | Introduction: On a reinvigorated HIV vaccine R&D fields and the promises and challenges of mRNA as a platform for the development of an HIV vaccine. *Susan Buchbinder, San Francisco Department of Public Heath, United States |
| 8:05 8 min | IAVI/Moderna studies (G001,G002,G003) *Bill Schief, Scripps Research / IAVI's Neutralizing Antibody Center (NAC), United States |
| 8:13 8 min | HVTN 302 *Sharon Riddler, University of Pittsburgh, United States |
| 8:21 8 min | Differences in developing a vaccine for HIV vs. COVID *Georgia Tomaras, Duke Human Vaccine Institute, United States |
| 8:29 30 min | Panel discussion *Susan Barnett, Bill & Melinda Gates Foundation, United States Julien Nyombayire Zambia Health Research Group - Projet San Francisco/Center for Family Health Research, Rwanda *Ntando Yola, Desmond Tutu HIV Foundation (DTHF), South Africa |
Oral Abstract Session, OALBA01
| 11:45 2 min | Introduction Brad Jones, Weill Cornell Medicine, United States |
| 11:47 8 min | Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial *Avi Kenny, Department of Biostatistics, University of Washington, United States |
| 11:55 8 min | FIt3 agonist enhances immunogenicity of arenavirus-vector based vaccines in macaques Brie Falkard, Gilead Sciences, Inc, United States |
| 12:03 8 min | Metabolomic and lipidomic correlates of time-to-HIV-rebound in viremic controllers treated with vesatolimod Yanhui Cai, Gilead Sciences, United States |
| 12:11 34 min | Q&A Brad Jones, Weill Cornell Medicine, United States Yanhui Cai, Gilead Sciences, United States *Avi Kenny, Department of Biostatistics, University of Washington, United States Brie Falkard, Gilead Sciences, Inc, United States |
Global Village Session Presentation with Q&A, GVSY06
Sunday, July 31
Prime Session, PR04
| 9:15 3 min | Introduction Jerome Kim, International Vaccine Institute (IVI), Korea, Republic of Diana Finzi, National Institutes of Health, United States |
| 9:18 15 min | In pursuit of an HIV vaccine *Glenda Gray, South African Medical Research Council, South Africa |
| 9:33 15 min | Immunotherapies towards an HIV cure Thomas Aagaard Rasmussen, Aarhus University Hospital, Denmark |
| 9:48 17 min | Q&A Jerome Kim, International Vaccine Institute (IVI), Korea, Republic of Diana Finzi, National Institutes of Health, United States *Glenda Gray, South African Medical Research Council, South Africa |
| 10:05 2 min | Closing remarks Jerome Kim, International Vaccine Institute (IVI), Korea, Republic of Diana Finzi, National Institutes of Health, United States |
| 10:07 8 min | IAS CPP Research-for-Cure Academy Fellowship |
Oral Abstract Session, OAB01
| 10:30 2 min | Introduction Tonia Poteat, University of North Carolina, United States |
| 10:32 8 min | Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV Christine Dang, University of Miami, United States |
| 10:40 8 min | Impact of gender identity- and HIV-related stigmas and psychosocial resources on mental health and alcohol use among transgender women newly diagnosed with HIV in India: a longitudinal cohort study Viraj Patel, Albert Einstein College of Medicine, Montefiore Medical Center, United States |
| 10:48 8 min | Forty-eight week outcomes of a combined cognitive behavioral therapy and medication management algorithm for treatment of depression among youth living with HIV in the United States (IMPAACT 2002) *Larry Brown, Rhode Island Hospital, United States |
| 10:56 8 min | Long-term risk of hospitalization and chronic disease among children who were HIV-exposed uninfected (cHEU) compared to population controls in Montreal, Canada Jeanne Brochon, Hopital Sainte Justine, Canada |
| 11:04 26 min | Q&A Christine Dang, University of Miami, United States Tonia Poteat, University of North Carolina, United States Viraj Patel, Albert Einstein College of Medicine, Montefiore Medical Center, United States *Larry Brown, Rhode Island Hospital, United States Jeanne Brochon, Hôpital Sainte Justine, Canada |
Symposium, SY21
| 14:15 5 min | Introductory notes on why we need to consider mAbs as a potential tool for HIV prevention Helen Rees, Wits RHI, ECHO Committee Consortium, South Africa |
| 14:20 10 min | Can we design, develop and manufacture antibodies that are effective, affordable and easy to deliver? Evidence from the pipeline Devin Sok, International AIDS Vaccine Initiative, United States |
| 14:30 45 min | Panel discussion Rachel Baggaley, World Health Organization, Switzerland *Lynda Stranix-Chibanda, University of Zimbabwe, Zimbabwe Carmen Perez Casas, Unitaid, Switzerland Sharonann Lynch, O'Neill Institute for National and Global Health Law, United States Helen Rees, Wits RHI, ECHO Committee Consortium, South Africa Devin Sok, International AIDS Vaccine Initiative, United States |
Global Village Session Presentation with Q&A, GVSY24
Monday, August 1
Oral Abstract Session, OALBB01
| 11:45 2 min | Introduction Brenda Crabtree-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico |
| 11:47 8 min | Phase I/II study of monoclonal antibody VRC01 with early antiretroviral therapy to promote clearance of HIV-1 infected cells in infants (IMPAACT 2008) *Alka Khaitan, Indiana University School of Medicine, United States |
| 11:55 8 min | Enhanced tuberculosis screening using computer-aided X-ray diagnosis and novel point of care urine lipoarabinomannan assay among adults with HIV admitted to hospital (CASTLE study): a cluster randomised trial Rachael Burke, Malawi Liverpool Wellcome Trust, Malawi |
| 12:03 8 min | The “City of Hope” Patient: prolonged HIV-1 remission without antiretrovirals (ART) after allogeneic hematopoietic stem cell transplantation (aHCT) of CCR5-?32/?32 donor cells for acute myelogenous leukemia (AML) Jana Dickter, City of Hope, United States |
| 12:11 8 min | Incident tuberculosis as a risk factor for viral non-suppression 48 weeks among patients switched to dolutegravir based therapy with recycled nucleoside reverse transcriptase inhibitors in Lusaka, Zambia Nyuma Mbewe, University Teaching Hospital, Lusaka Zambia |
| 12:19 26 min | Q&A Rachael Burke, Malawi Liverpool Wellcome Trust, Malawi Nyuma Mbewe, University Teaching Hospital, Lusaka Zambia *Alka Khaitan, Indiana University School of Medicine, United States Jana Dickter, City of Hope, United States Brenda Crabtree-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico |
Symposium, SY34
| 14:15 2 min | Introduction *Glenda Gray, South African Medical Research Council, South Africa Amy Chung, The University of Melbourne, Australia |
| 14:17 12 min | mRNA vaccine *Barton Haynes, Duke Human Vaccine Institute and the Center for HIV-AIDS Vaccine Immunology, United States |
| 14:29 12 min | First-in-human Phase 1 trials with SOSIP Env trimers Godelieve de Bree, Amsterdam UMC, Netherlands |
| 14:41 12 min | Overcoming 'improbable mutations' *Kevin Saunders, Duke University School of Medicine, United States |
| 14:53 12 min | bNAB infusion *Lynn Morris, National Institute for Communicable Diseases, South Africa |
| 15:05 10 min | Q&A *Glenda Gray, South African Medical Research Council, South Africa Amy Chung, The University of Melbourne, Australia *Barton Haynes, Duke Human Vaccine Institute and the Center for HIV-AIDS Vaccine Immunology, United States Godelieve de Bree, Amsterdam UMC, Netherlands *Kevin Saunders, Duke University School of Medicine, United States *Lynn Morris, National Institute for Communicable Diseases, South Africa |
Oral Abstract Session, OAE03
| 14:15 2 min | Introduction Viviane D. Lima, British Columbia Centre for Excellence in HIV/AIDS, Canada |
| 14:17 8 min | The effect of a conditional cash transfer program on AIDS morbidity and mortality among the poorest: a quasi-experimental study of a cohort of 22.7 million Brazilians Davide Rasella, Instituto de Saude Coletiva, Federal University of Bahia, Brazil |
| 14:25 8 min | Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for all infants born in high-burden settings Caitlin Dugdale, Massachusetts General Hospital, United States |
| 14:33 8 min | The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis: a modelled economic evaluation and threshold analysis in South Africa based on the HPTN 083 and 084 trials *Gesine Meyer-Rath, Health and Epidemiology Research Office, University of the Witwatersrand, South Africa |
| 14:41 8 min | Variation in average unit prices (2020) of antiretroviral drugs in generic accessible low- and middle-income countries Deepak Mattur, UNAIDS, Switzerland |
| 14:49 26 min | Q&A Davide Rasella, Instituto de Saude Coletiva, Federal University of Bahia, Brazil Caitlin Dugdale, Massachusetts General Hospital, United States *Gesine Meyer-Rath, Health and Epidemiology Research Office, University of the Witwatersrand, South Africa Deepak Mattur, UNAIDS, Switzerland Viviane D. Lima, British Columbia Centre for Excellence in HIV/AIDS, Canada |
Satellie Session, SA098
| 17:45 3 min | Introduction *Julie Ake, U.S. Military HIV Research Program, United States |
| 17:48 10 min | 1. Better products, new platforms, new strategies: what COVID-19 has changed in HIV vaccine science *Dan Barouch, Center for Virology and Vaccine Research, BIDMC, United States |
| 17:58 10 min | 2. What has COVID-19 changed in clinical trial management *Fatima Laher, Director of the PHRU Vaccines Research Centre, South Africa |
| 18:08 10 min | 3. Community engagement in clinical research: Better prepared, better engaged? |
| 18:18 10 min | 5. Regulatory approval: Are we better prepared for a successful HIV vaccine? *Helen Rees, Wits RHI, ECHO Committee Consortium, South Africa |
| 18:25 50 min | Panel discussion-Promise held or still much more to do. |
Tuesday, August 2
Satellite Session, SA105
| 8:00 5 min | Introduction *Helen Ayles, Zambart, Zambia |
| 8:05 10 min | 1. Summary of PopART design and main findings *Sarah Fidler, Imperial College London, United Kingdom |
| 8:15 10 min | 2. What have we learned from subsequent analysis to better understand our main findings and effects on TB *Richard Hayes, London School of Hygiene and Tropical Medicine, United Kingdom |
| 8:25 10 min | 3. New data and findings including phylogenetic analysis *Christophe Fraser, Big Data Institute, United Kingdom |
| 8:35 10 min | 4. Where do we go from here - messages for policy/implementation *Helen Ayles, Zambart, Zambia |
| 8:45 15 min | Panel discussion *Rachel Baggaley, World Health Organization, Switzerland *Siobhan Crowley, The Global Fund, Switzerland *Helen Ayles, Zambart, Zambia *David Serwadda, Makerere University, Uganda *Sarah Fidler, Imperial College London, United Kingdom *Richard Hayes, London School of Hygiene and Tropical Medicine, United Kingdom |
Oral Abstract Session, OALBC01
| 11:45 2 min | Introduction Ayesha Kharsany, CAPRISA, South Africa |
| 11:47 8 min | High prevalence of asymptomatic Omicron carriage and correlation with CD4+ T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa *Jessica Andriesen, Fred Hutchinson Cancer Center, United States |
| 11:55 8 min | A phase IV open-label evaluation of valuation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1 Lijun Sun, Beijing Youan Hospital, Capital Medical University, China |
| 12:03 8 min | National roll out of community HIV screening among key populations in Indonesia: assessment of early results Budi Utomo, Universitas Indonesia, Indonesia |
| 12:11 8 min | Predictors of high viral load among adult HIV recipients of care in Zambia, 2021: a cross-sectional analysis of HIV case-based surveillance data Sulani Nyimbili, Centre for Infectious Diseases Research, Zambia |
| 12:19 26 min | Q&A Ayesha Kharsany, CAPRISA, South Africa Lijun Sun, Beijing Youan Hospital, Capital Medical University, China Sulani Nyimbili, Centre for Infectious Diseases Research, Zambia Budi Utomo, Universitas Indonesia, Indonesia *Jessica Andriesen, Fred Hutchinson Cancer Center, United States |
Poster Exhibition and E-Posters
| Associated Protocols | Abstract Title | Presenting Author | Format |
| HVTN 805 /HPTN 093 | EPLBB08: Analytical Treatment Interruption (ATI) Among African Women with Early ART Initiation with or without VRC01 Circulating at HIV Acquisition: Study Design and Early Observations of Viral Rebound and Control | Shelly Karuna | E-poster |
| IMPAACT 2002 | EPB222: Participant Acceptability and Clinician Satisfaction of Cognitive Behavioral Therapy and a Medication Management Algorithm Compared with Enhanced Standard Care for Treatment of Depression among Youth Living with HIV | Lauren Bergam | E-poster |
| IMPAACT 2017 | PEMOB29: Selection of Cabotegravir Dosing Regimens for HIV Treatment and Pre-exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data | Mark Baker | Poster exhibition |
| Associated Protocols | Abstract Title | Presenting Author | Format |
| HVTN 071 | PEMOC36: The effect of universal testing and treatment for HIV on health-related quality of life – data from the HPTN 071 (PopART) cluster randomised trial in Zambia and South Africa | Katherine Davis | Poster Exhibition |
| HPTN 083 | EPLBC04: Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions with Long-acting Cabotegravir (CAB-LA) | Beatriz Grinsztejn | E-poster |
| HPTN Modelling Centre | EPC150: Population-Level Impact of Expanding PrEP Coverage Among Men Who Have Sex with Men with Long-Acting Injectable Cabotegravir: Model Comparison Analysis for Atlanta, U.S. and Montreal, Canada | Sarah Stansfield | E-poster |
| Associated Protocols | Abstract Title | Presenting Author | Format |
| HPTN 068 | EPD151: Trajectories of Depressive Symptoms and HIV-Related Sexual Behaviors Among Adolescent Girls and Young Women in Rural South Africa (HPTN 068) | Nivedita Bhushan | E-poster |
| HPTN 068 | EPD158: Effects of Quality of Caregiver-Adolescent Relationship on HIV, HSV-2 and on Pregnancy Incidence Among Young Women in Rural South Africa Enrolled in HPTN 068 | Nosipho Shangase | E-poster |
| HPTN 071 | EPD028: Mobility and HIV Transmission Across Three Urban Communities in Zambia: Using Qualitative Data to Interpret Phylogenetics in a Mixed Methods Analysis of HPTN 071 (PopART) Data | Melvin Simuyaba | E-poster |
| HPTN 082 | EPD339: Motivations for Starting, Stopping and Restarting Oral PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial | Lisa Mills | E-poster |
| HPTN 084 | EPD103: Acceptability of Injectable Cabotegravir Versus Daily Oral TDF/FTC for PrEP: Lesson from HPTN 084 | Nomhle Khoza | E-poster |
| HVTN 706 | EPD004: Utilizing standardized metrics to track recruitment strategies in a global preventive HIV vaccine study during the COVID-19 pandemic | Rafael Gonzalez | E-poster |
| Associated Protocols | Abstract Title | Presenting Author | Format |
| N/A | EPE331: The Representative Studies Rubric: 12 steps to address underrepresentation in HIV clinical research | Brian Minalga | E-poster |